NCT05598320View on ClinicalTrials.gov

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

August 9, 2024

Study Completion Date

August 31, 2025

Conditions
Achondroplasia
Interventions
DRUG

TransCon CNP

Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP

DRUG

Placebo for TransCon CNP

Once-weekly subcutaneous injection of 100 µg/kg placebo for TransCon CNP

Trial Locations (10)

1008

Ascendis Pharma Investigational Site, Vitoria-Gasteiz

1023

Ascendis Pharma Investigational Site, Auckland

2100

Ascendis Pharma Investigational Site, Copenhagen

3052

Ascendis Pharma Investigational Site, Parkville

53705

Ascendis Pharma Investigational Site, Madison

55102

Ascendis Pharma Investigational Site, Saint Paul

65212

Ascendis Pharma Investigational Site, Columbia

77030

Ascendis Pharma Investigational Site, Houston

H3T 1CS

Ascendis Pharma Investigational Site, Montreal

D01 YC76

Ascendis Pharma Investigational Site, Dublin

All Listed Sponsors
lead

Ascendis Pharma Growth Disorders A/S

INDUSTRY